Post-earnings recap
Reported
Tue, May 13, 2025
EPS actual
$-0.45
EPS est.
$-0.39
EPS surprise
-15.38%
1-day move
-3.90%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
CG Oncology's first-quarter results indicate ongoing challenges, particularly reflected in the EPS miss. The stock's 3.9% decline suggests investor disappointment. Without revenue figures or guidance, uncertainty remains about the company's short-term outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.45 | N/A | -15.38% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed concern about the current performance while maintaining a focus on future growth strategies.
Management acknowledged the challenges faced this quarter.
They emphasized a focus on long-term strategies despite current setbacks.